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Exclusively dopamine producing retroperitoneal paragangliomas are extremely rare. We have experienced the first Korean 
case managed successfully based on the proper evaluation. A 26-year-old female patient came to our attention after the acci-
dental detection of an adrenal mass. She had no symptoms and denied any family history. Laboratory evaluations were nor-
mal but serum dopamine (425 ng/L) and 24-hour urine dopamine levels (1,565.3 μg/day) were elevated. She underwent lapa-
roscopic right adrenalectomy. Histopathological diagnosis was a paraganglioma. After operation, dopamine levels in serum 
and 24-hour urine dropped to 0.09 ng/L and 388.4 μg/day. Dopamine producing paraganglioma elicit no clinical symptoms. 
Only the dopamine level is elevated in serum and 24-hour urine samples. Surgical resection without using preoperative al-
pha blockage is the treatment of choice. The prognosis for patients with this tumor tends to be poor because the diagnosis is 
usually delayed due to lack of symptoms.
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INTRODUCTION
Pheochromocytomas or paragangliomas are rare neu-
roendocrine tumor that arise from chromaffin cells. The 
tumor produces catecholamines, such as norepinephrine 
and epinephrine, and leads to well-known clinical symp-
toms, such as hypertension, headache, sweating, palpita-
tion, and orthostatic hypertension. 
A pheochromocytoma or a paraganglioma that exclu-
sively secretes dopamine is extremely rare. It is usually 
found at extra-adrenal sites and is diagnosed as a subtype 
of paraganglioma. The high dopamine level in this tumor 
is caused by a deficiency in dopamine-beta-hydroxylase, 
which converts dopamine to norepinephrine [1]. For this 
reason, this tumor differs from classic pheochromocyto-
mas in many respects, not only in its clinical features but 
also in its oncologic aspect. Only two original articles and 
five case reports have reported the occurrence of dopa-
mine secreting paragangliomas in the retroperitoneum 
around the adrenal glands [2-8].Jin Wook Yi, et al.
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Fig. 1. Computed tomography scan shows hypervascular mass 
with dimensions of 4.3 × 3.2 cm on right adrenal gland with early 
washout enhancing pattern. Mass abuts against inferior vena cava 
(arrow). Fig. 2. Magnetic resonance imaging showing 2.8 cm sized mass in 
right periadrenal area with slightly high signal intensity in T2 
weighted image. Mass abuts against and compresses right adrenal 
gland laterally and inferior vena cava medially (arrow). We experienced the first case in Korea in an asympto-
matic woman. We report this interesting case and establish 
clinical concepts for this rare tumor by reviewing the re-
lated literature. 
CASE REPORT
A 26-year-old Korean woman was referred after the ac-
cidental detection of an adrenal mass in her right side. She 
denied any medical history including endocrine disorders. 
There was no family history of endocrine disease. She had 
no hypertension, palpitation, sweating, headache, flank 
pain, or mass upon palpation of her abdomen. 
On physical examination, her blood pressure was 110/ 
90 mmHg and her heart rate was 90 beats/min. The results 
of laboratory tests, including a complete blood count and 
liver and renal function tests, were all unremarkable. The 
results of an overnight 1 mg dexamethasone suppression 
test were normal. Serum norepinephrine and epinephrine 
levels were normal but the dopamine level was high (425 
ng/L). Analysis of a 24-hour urine sample revealed marked 
elevation of the urinary dopamine level (1,565.3 μg/day) 
but normal levels of vanillylmandelic acid (VMA), nor-
epinephrine, epinephrine, metanephrine and normetane-
phrine.  
Computed tomography results showed a 4.3 × 3.2 cm 
hypervascular mass on the right adrenal gland with an 
early washout enhancement pattern. The mass abutted 
against the inferior vena cava (IVC) (Fig. 1). Magnetic reso-
nance imaging revealed a 2.8 cm sized tumor that was lo-
cated in the right periadrenal area and that abutted against 
the adrenal gland laterally and IVC medially (Fig. 2).
Our preoperative diagnosis was a dopamine producing 
paraganglioma in the right retroperitoneum. She was not 
administered a preoperative α-blocker or any anti-hyper-
tensive drug. Hand-assisted laparoscopic right adrenalec-
tomy was performed because of the firm attachment of the 
tumor to adjacent structures. En-bloc excision of the tumor 
and adrenal gland was performed (Fig. 3). Total operative 
time was 110 minutes and blood loss was minimal. Her 
blood pressure was continuously normal and there were 
no fluctuations in vital signs during the operation. She was 
discharged with no immediate postoperative complica-
tions. 
On the histologic report, the tumor measured 3.4 × 3.0 × 
2.5 cm. It was well encapsulated, homogenous and had a 
yellowish cut-surface with some internal hemorrhagic 
spots. Microscopic diagnosis was a neuroendocrine tumor 
whose clinical manifestations were consistent with those 
of a paraganglioma. Hematoxylin/eosin staining revealed 
vascular invasion and extension to peritumoral adipose Exclusively dopamine secreting paraganglioma in retroperitoneum
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Fig. 3. Intraoperative view under videoscope. After careful dissection around tumor, tumor was removed successfully with assistance of 
surgeon’s left hand (arrow).
Fig. 4. Microscopic findings (×40). (A) Hematoxylin/eosin staining revealed peritumoral adipose tissue extension and vascular invasion. 
Immunohistochemistry results were positive for neuroendocrine markers CD56 (B), synaptophysin (C), and chromogranin (D). The Ki-67 (E) 
index was less than 1%. S-100 (F) was negative.
tissue. An immunohistochemical study showed that the 
tumor was positive for neuroendocrine markers such as 
CD-56, synaptophysin and chromogranin. The tumor had 
a Ki-67 index of less than 1 percent and was negative for 
S-100 (Fig. 4).
Her 24-hour urine dopamine level returned to normal 
(388.4 μg/day) after the operation. Her general condition 
was good and there was no recurrence during a 10-month 
follow-up. 
DISCUSSION
Among the many types of paraganglioma, an exclusi-
vely dopamine producing type is extremely rare. Only 
seven cases are listed in the worldwide database and no Jin Wook Yi, et al.
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case has ever before been reported in South Korea [2-8].
The exclusive production of dopamine can be ascribed 
to a deficiency in dopamine β-hydroxylase which converts 
dopamine to norepinephrine in the catecholamine biosyn-
thesis pathway beginning with tyrosine [1,4,8]. Because of 
the abnormal catecholamine synthesis pathway, the levels 
of dopamine and its end product, homovanillic acid (HVA), 
are increased, whereas the levels of norepinephrine, epi-
nephrine and their end product, VMA, are decreased. In 
consequence, the clinical presentation of this tumor is dif-
ferent from that of a classical pheochromocytoma that se-
cretes norepinephrine and epinephrine. There is an absence 
of hemodynamic changes or so-called paroxysmal symp-
toms that are usually found in patients with catechol-
amine secreting pheochromocytoma. As a result, the pa-
tients with exclusively dopamine producing paraganglio-
ma are mostly asymptomatic at initial diagnosis. Some 
constitutional symptoms such as fever, malaise, weight 
loss or diarrhea may occur as a result of the increased cir-
culating dopamine level. Because paragangliomas tend to 
grow larger than adrenal pheochromocytomas, some pa-
tients experience vague abdominal pain or experience a 
palpable abdominal mass [4-8]. The asymptomatic fea-
tures make it difficult for clinicians to detect the tumor at 
an early stage. Detection is even more challenging to 
physicians working in institutes without routine screen-
ing procedures for the detection of catecholamine and 
dopamine.
Differential diagnosis can be achieved by measuring the 
dopamine levels in serum and 24-hour urine samples. 
Clinicians should not rule out the possibility of this rare 
tumor when evaluating adrenal masses with normal se-
rum norepinephrine, epinephrine and urinary VMA lev-
els, even if the radiologic images strongly suggest a pheo-
chromocytoma.
The treatment of every adrenal tumor should involve 
complete surgical excision. Laparoscopic surgery is con-
sidered the standard surgical option. Hand-assisted lapa-
roscopic surgery has been adapted for the removal of large 
tumors and for the rescue of operative procedures in com-
plicated cases of laparoscopic surgery [9].
To minimize surgical mortality caused by hypertensive 
crisis during the manipulation of the tumor, preoperative 
administration of a α-blocker is essential for norepine-
phrine and epinephrine producing pheochromocytomas. 
However, α-blocker treatment is contraindicated for ex-
clusively dopamine secreting paraganglioma because it 
can cause profound cardiovascular collapse after surgery, 
and can even result in death following a hypotensive crisis 
[8]. The explanation for this fatal outcome is as follows. 
First, unlike norepinephrine and epinephrine, dopamine 
has no affinity for the α-receptor. Second, it has been sug-
gested that dopamine can lower blood pressure by itself. 
There are two subtypes of dopamine receptors; the D1 re-
ceptor, which relaxes smooth muscles in blood vessels, 
and the D2 receptor, which inhibits noradrenaline release 
from postganglionic sympathetic neurons. These two ef-
fects could explain the pre-operative hypotension in dop-
amine secreting tumor patients. Blood pressure is some-
times elevated after the removal of this tumor presumably 
because of the same mechanism [4,5]. 
Dopamine secreting paragangliomas are more likely to 
present malignant features than classic catecholamine se-
creting type paragangliomas or pheochromocytomas. This 
rare tumor tends to be diagnosed in patients who are 
asymptomatic, and the tumor is detected later than tu-
mors that secrete norepinepnrine, epinephrine or both. 
Delayed diagnosis may be related to the higher incidence 
of malignant transformation and metastasis. Concerning 
the biochemical features, one report suggests that the de-
creased activity of dopamine β-hydroxylase results in 
poor differentiation of this tumor, which may explain why 
the dopamine-secreting type shows advanced malignant 
features [10]. There are known risk factors for judging the 
malignant potential of paragangliomas. Elevated dopa-
mine or HVA levels in 24-hour urine (＞120 nmol/g) is cor-
related with large tumor size and malignant potential. 
Extra-adrenal location, a tumor weight of more than 80 g, 
DNA aneuploidy or triploidy and persistent postopera-
tive hypertension have also been reported as risk factors 
for malignant pheochromocytoma [10]. Because of the rar-
ity of this tumor, there are no definite criteria for evaluat-
ing its malignant potential. 
In conclusion, exclusively dopamine secreting para-
gangliomas are extremely rare. Lack of clinical symptoms 
and the rarity of this tumor can lead to the lack of, or a de-Exclusively dopamine secreting paraganglioma in retroperitoneum
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lay in diagnosis. In addition to radiologic imaging, dopa-
mine assays in serum and 24-hour urine collection are use-
ful diagnostic tests. Laparoscopic tumor removal is the 
treatment of choice without administration of a preope-
rative α-blocker. Prognosis is known to be poorer than that 
for pheochromocytomas. 
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article 
was reported.
REFERENCES
1. Feldman JM, Blalock JA, Zern RT, Shelburne JD, Gaede JT, 
Farrell RE, et al. Deficiency of dopamine-beta-hydroxylase. 
A new mechanism for normotensive pheochromocytomas. 
Am J Clin Pathol 1979;72:175-85.
2 . P r o y e  C ,  F o s s a t i  P ,  F o n t a i n e  P ,  L e f e b v r e  J ,  D e c o u l x  M ,  
Wemeau JL, et al. Dopamine-secreting pheochromocyto-
ma: an unrecognized entity? Classification of pheochro-
mocytomas according to their type of secretion. Surgery 
1986;100:1154-62.
3. Eisenhofer G, Goldstein DS, Sullivan P, Csako G, Brouwers 
FM, Lai EW, et al. Biochemical and clinical manifestations 
of dopamine-producing paragangliomas: utility of plasma 
methoxytyramine. J Clin Endocrinol Metab 2005;90:2068- 
75.
4. Dubois LA, Gray DK. Dopamine-secreting pheochromocy-
tomas: in search of a syndrome. World J Surg 2005;29:909- 
13.
5. Tam V, Ng KF, Fung LM, Wong YY, Chan MH, Lam CW, et 
al. The importance of the interpretation of urine catechol-
amines is essential for the diagnosis and management of 
patient with dopamine-secreting paraganglioma. Ann Clin 
Biochem 2005;42(Pt 1):73-7.
6. Awada SH, Grisham A, Woods SE. Large dopamine-secret-
ing pheochromocytoma: case report. South Med J 2003;96: 
914-7.
7. Yasunari K, Kohno M, Yoshikawa J. A dopamine-secreting 
pheochromocytoma. Am J Med 1999;106:599-600.
8. Foo SH, Chan SP, Ananda V, Rajasingam V. Dopamine-se-
creting phaeochromocytomas and paragangliomas: clini-
cal features and management. Singapore Med J 2010;51: 
e89-93.
9. Sata N, Shiozawa M, Suzuki A, Kurihara K, Ohki J, Nagai 
H. Retroperitoneal hand-assisted laparoscopic surgery for 
endoscopic adrenalectomy. Surg Endosc 2006;20:830-3.
10. Schlumberger M, Gicquel C, Lumbroso J, Tenenbaum F, 
Comoy E, Bosq J, et al. Malignant pheochromocytoma: 
clinical, biological, histologic and therapeutic data in a ser-
ies of 20 patients with distant metastases. J Endocrinol 
Invest 1992;15:631-42.